Journal of Pharmaceutical Investigation

The Korean Society of Pharmaceutical Sciences and Technology (한국약제학회)
권호 표지
DOI QR코드

DOI QR Code

CR 2945-Conjugated Liposomes for Targeting of Human Pancreatic Cancer Cells

  • Yoon, Na-Young (College of Pharmacy, Sookmyung Women's University) ;
  • Kim, Jin-Seok (College of Pharmacy, Sookmyung Women's University)
  • Published : 2004.12.20
Download PDF
⟨ Previous Next ⟩

Abstract

CR 2945, a $gastrin/CCK_B$ receptor antagonist, was conjugated to liposome and tested for the targeting of pancreatic cancer cells in vitro. Successful conjugation was confirmed by FTIR and NMR. The size of CR 2945-conjugated liposome was about 500 nm in diameter, with the zeta-potential being -16.5 mV. In vitro anti-cancer activity of this formulation with or without gemcitabine encapsulated was tested on human pancreatic cancer cells, PANC-1. The growth inhibitory effect of gemcitabine-encapsulating CR 2945-conjugated liposome was found to be 10-fold more potent than that of gemcitabine-encapsulating non-conjugated liposome, suggesting that CR 2945 could be used as a potential cancer targeting moiety by conjugating into liposome.

Keywords

References

  1. S. Tominaga and T. Kuroishi, Epidemiology of pancreatic cancer, Semin. Surg. Oncol., 15, 3-7 (1998) https://doi.org/10.1002/(SICI)1098-2388(199807/08)15:1<3::AID-SSU2>3.0.CO;2-9
  2. S.M. de Lange, C.J. van Groeningen, O.W.M. Meijer, M.A. Cuesta, J.A. Langendijk, J.M.G.H. van Riel, H.M. Pinedo, G. J. Peter,s, S. Meijer, BJ. Slotman and G. Giaccone, Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer, Eur. J. Cancer, 38, 1212-1217 (2002) https://doi.org/10.1016/S0959-8049(02)00076-X
  3. M.G. Fontana, E Donato, V. Villanacci, M. Ghirardi, D. Moneghini, E.D. Betta and B. Salemi, Inhibitory effect of a gasrin receptor antagonist, CR2945, on 1,2-dimethylhydrazine- induced colorectal cancer in mice, Eur. Surg. Res., 31, 406-411 (1999) https://doi.org/10.1159/000008719
  4. R.H. Paulssen, N. Fraeyman and J. Florholmen, Activation of phospholipase C by cholecystokinin receptor subtypes with different G-protein-coupling specificities in hormone-secreting pancreatic cell lines, Bioehem. Pharmaeol., 60(6), 865-875 (2000)
  5. F. Makovec, L. Revel, O. Letari, L. Mennuni and M. Impicciatore, Characterization of antisecretory and antiulcer activity of CR 2945, a new potent and selective gastrin/CCKB receptor antagonist, Eur. J. Pharmaeol., 369(1), 81-90 (1999) https://doi.org/10.1016/S0014-2999(99)00069-2
  6. W. Plunkett, P. Huang, YZ. Xu, V. Heinemann, R Grunewald and V. Gandhi, Gemcitabine : metabolism, mechanisms of action, and self-potentiation, Semin. Oneol., 22(4), Suppl. 11, 3-10 (1995)
  7. I.B. Nilsson, S.P. Svensson and H.J. Monstein, Molecular cloning of a putative Ciona intestinalis cionin receptor, a new member of the CCK/gastrin receptor family, Gene, 323(24), 79-88 (2003) https://doi.org/10.1016/j.gene.2003.09.002
  8. M. Ono, H. Sato, H. Kazumori, M. Yuki, M. Rumi, C.O. Cava, Y. Ishihara, S. Ishihara, K. Adachi and Y. Kinoshita, Effect of a gastrin/cholecystokinin B receptor antagonist, S-0509, on the omeprazole-induced proliferation of gastric mucosa in rats, J. Lab. Clin. Med., 142(6), 364-371 (2003) https://doi.org/10.1016/S0022-2143(03)00151-3
  9. El Martin, T.D. Heath and R.R.C. New, Liposomes: anpractical approach, IRL press, 163-182 (1990)
  10. A.D. Gilliam and S.A. Watson, Emerging biological therapies for pancreatic carcinoma, Eur. J. Sur. Oneol., 28, 370-378 (2002) https://doi.org/10.1053/ejso.2001.1248
  11. E.G. Bligh and W.J. Dyer, A rapid method of total lipid extraction and purification, Can. J. Biochem. Physiol., 37, 911-917 (1959) https://doi.org/10.1139/o59-099
  12. B. P. van Putte, J.M.H. Hendriks, S. Romijn, B. Pauwels, G. de Boeck, G. Guetens, E. de Bruijn and P.E.Y. van Schil, Pharmacokinetics after pulmonary artery perfusion with gemcitabine, Ann. Thorae. Surg., 76(4), 1036-1040 (2003) https://doi.org/10.1016/S0003-4975(03)00839-7
  13. M.T. Fields, A. Eisbruch, D. Normolle, A. Orfali, M.A. Davis, A.T. Pu and T.S. Lawrence, Radiosensitization produced in vivo by once- vs. twice-weekly 2'2'-difluoro-2'-deoxycytidine (gemcitabine), Int. J. Radiat. Oneol. BioI. Phys., 47(3), 785-791 (2000) https://doi.org/10.1016/S0360-3016(00)00447-8